Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

Abstract:

OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The enhanced conduction along demyelinated axons promoted by dalfampridine could potentially lead to development of positive neurologic phenomena. METHODS:We reviewed the medical records of patients who were started on dalfampridine for activation of positive sensory or motor symptoms. RESULTS:Four of 76 patients (5.3%) developed positive sensory symptoms within one month of starting dalfampridine; one additional patient had new-onset seizure. Cessation of dalfampridine was insufficient to resolve symptoms in two patients with recurrent trigeminal neuralgia. CONCLUSIONS:Initiation of dalfampridine may be associated with initiation or recurrence of positive sensory symptoms in patients with multiple sclerosis. The increased axonal conduction from potassium channel blockade may contribute to this exacerbation of positive sensory phenomena.

authors

Thaera GM,Wingerchuk DM,Carter JL

doi

10.1016/j.msard.2013.05.003

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

107-9

issue

1

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(13)00050-3

journal_volume

3

pub_type

杂志文章
  • Construct validity and test-retest reliability of the Swedish version of the Acceptance of Chronic Health Conditions Scale.

    abstract::The Acceptance of Chronic Health Conditions Scale was developed to measure acceptance in chronic health conditions like multiple sclerosis (MS) and has been translated into Swedish (The Swedish Acceptance of Chronic Health Conditions Scale). The purpose of the present study was to evaluate construct validity and test-...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.07.033

    authors: Wallin A,Forslin M,Johansson S,Kierkegaard M

    更新日期:2019-10-01 00:00:00

  • FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) unmasked by withdrawal of immunosuppression for Crohn's disease?

    abstract::A 31-year-old pregnant woman presented with headache, fever and left-sided focal motor seizures, which progressed to bilateral tonic-clonic seizures. Her medical history included Crohn's disease treated with azathioprine and adalimumab, which were discontinued when she became pregnant. Her cerebro-spinal fluid was ent...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102729

    authors: Stamenova S,Redha I,Schmierer K,Garcia ME

    更新日期:2020-12-31 00:00:00

  • Screening of dysphagia by DYMUS (Dysphagia in multiple sclerosis) and SWALQoL (Swallowing quality of life) surveys in patients with multiple sclerosis.

    abstract:BACKGROUND:Dysphagia is a life-threating symptom in patients with multiple sclerosis (MS) because aspiration pneumonia develops as a consequence of swallowing disorders. Dysphagia can be detected by using patient-reported outcome measures in order to prevent complications. OBJECTIVE:To identify the dysphagia prevalenc...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102397

    authors: Tahir E,Kavaz E,Kemal Ö,Şen S,Terzi M

    更新日期:2020-10-01 00:00:00

  • Mining healthcare data for markers of the multiple sclerosis prodrome.

    abstract:BACKGROUND:Previous studies suggest the existence of a prodromal period in multiple sclerosis, but little is known about the phenotypic characteristics. This study aims to characterize the multiple sclerosis (MS) prodrome using data mining analytics in the healthcare setting. METHODS:We identified people with MS and m...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.08.007

    authors: Högg T,Wijnands JMA,Kingwell E,Zhu F,Lu X,Evans C,Fisk JD,Marrie RA,Zhao Y,Tremlett H

    更新日期:2018-10-01 00:00:00

  • A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics.

    abstract::Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2016.03.019

    authors: Solomon AJ,Bernat JL

    更新日期:2016-05-01 00:00:00

  • Protective stepping in multiple sclerosis: Impacts of a single session of in-place perturbation practice.

    abstract:OBJECTIVES:To evaluate the impact of a single day of protective stepping practice in individuals with Multiple Sclerosis (MS). BACKGROUND:Multiple Sclerosis is a leading cause of disability among young adults in the United States. Gait and balance dysfunction are both widespread in MS and strong predictors of falls, d...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.054

    authors: Van Liew C,Dibble LE,Hunt GR,Foreman KB,Peterson DS

    更新日期:2019-05-01 00:00:00

  • Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD).

    abstract:BACKGROUND:The 2015 criteria for diagnosing neuromyelitis optica spectrum disorder (NMOSD) have encouraged several groups across the world to report on their patients using these criteria. The disease typically manifests with severe relapses of optic neuritis, longitudinally extensive myelitis and/or brainstem syndrome...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.031

    authors: Fragoso YD,Sousa NAC,Alves-Leon SV,Dias RM,Pimentel MLV,Gomes S,Goncalves MVM,Stella CV,Tauil CB,Anacleto A,Spessotto CV,Correa EC,Eboni ACB,Damasceno A,Damasceno B,Farinhas JGD,Mota RSS,Nogueira EGA,Pereira VCSR,Sc

    更新日期:2019-01-01 00:00:00

  • Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.

    abstract:OBJECTIVE:To investigate the predictive factors associated with good outcomes of plasma exchange in severe attacks through neuromyelitis optica spectrum disorder (NMOSD) and long extensive transverse myelitis (LETM). In addition, to review the literature of predictive factors associated with the good outcomes of plasma...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.02.015

    authors: Aungsumart S,Apiwattanakul M

    更新日期:2017-04-01 00:00:00

  • New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases.

    abstract::Acquired demyelinating CNS syndromes include a broad spectrum of clinical phenotypes and different entities can overlap. Therefore, differential diagnosis is still challenging. A humoral immune reaction against myelin oligodendrocyte glycoprotein (MOG) is present in a subgroup of these patients, particularly in childr...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2018.02.023

    authors: Di Pauli F,Reindl M,Berger T

    更新日期:2018-05-01 00:00:00

  • Cognitive and physical fatigue are associated with distinct problems in daily functioning, role fulfilment, and quality of life in multiple sclerosis.

    abstract:OBJECTIVE:To examine whether cognitive and physical fatigue are differentially associated with problems in self-care, mobility, relationships, participation, psychological well-being, and quality of life in people with multiple sclerosis. METHODS:A cross-sectional study involving seventy-four community-dwelling people...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.03.024

    authors: Gullo HL,Fleming J,Bennett S,Shum DHK

    更新日期:2019-06-01 00:00:00

  • Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.

    abstract:BACKGROUND:Disease-modifying therapy (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS) have been shown to reduce relapses and new MRI lesions. However, few studies have assessed the impact of discontinuing DMT after a period of disease inactivity. OBJECTIVE:To investigate the impact of DMT disconti...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.07.021

    authors: Yano H,Gonzalez C,Healy BC,Glanz BI,Weiner HL,Chitnis T

    更新日期:2019-10-01 00:00:00

  • Validation of an algorithm to detect severe MS relapses in administrative health databases.

    abstract:BACKGROUND:Severe relapses that required treatment were important outcomes in the sentinel trials of disease-modifying therapy (DMT). Identifying such relapses in administrative data would allow comparative-effectiveness studies of DMTs to be conducted in real-world clinical settings. METHODS:All relapsing-remitting (...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.11.022

    authors: Marriott JJ,Chen H,Fransoo R,Marrie RA

    更新日期:2018-01-01 00:00:00

  • Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.

    abstract:BACKGROUND:Numerous factors can affect multiple sclerosis (MS) patients' quality of life (QoL). We investigated how physical impairment, upper extremity function, cognitive impairment, cognitive reserve, symptoms of psychological distress, depression, fatigue as well as age and disease duration contribute to patient-re...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.049

    authors: Yalachkov Y,Soydaş D,Bergmann J,Frisch S,Behrens M,Foerch C,Gehrig J

    更新日期:2019-05-01 00:00:00

  • Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease in the central nerve system, in which both innate and adaptive immune cells are involved. BBR3378, an aza-anthrapyrazole prevents experimental autoimmune encephalomyelitis (EAE), an inflammatory condition similar to MS, by antagonizing T...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102190

    authors: Lin B,Launder D,Bailey DY,Assifuah FK,Miller OA,Conti HR,Du J,Koffman BM

    更新日期:2020-08-01 00:00:00

  • Optic neuropathy: A 15-year retrospective observational study.

    abstract:BACKGROUND:Optic neuropathies (ON) have several aetiologies and sometimes the diagnosis established ab initio is redefined after further investigations and/or new neurological events. We aim with this study to report clinical, paraclinical findings, treatment choices and disease course in patients admitted with a suspi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102337

    authors: Alves JM,Seabra M,Braz L,Guimarães J

    更新日期:2020-09-01 00:00:00

  • Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.

    abstract:AIM OF THE STUDY:To investigate adherence to disease modifying therapy (DMT) in Lithuanian population of multiple sclerosis patients and factors associated to it. METHODS:Patients receiving one of the following DMT's: Interferon β 1a (Rebif) 44 micrograms three times a week subdermally (s/c) or Interferon β 1a (Avonex...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.02.016

    authors: Duchovskiene N,Mickeviciene D,Jurkeviciene G,Dirziuviene B,Balnyte R

    更新日期:2017-04-01 00:00:00

  • Olfactory dysfunction in multiple sclerosis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is a common chronic neurological disease that causes disability. MS can have various clinical manifestations, one of which is olfactory dysfunction. In clinical practice, olfactory disturbances are usually underdiagnosed. The aim of our study is to assess olfactory function and its re...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.02.032

    authors: Atalar AÇ,Erdal Y,Tekin B,Yıldız M,Akdoğan Ö,Emre U

    更新日期:2018-04-01 00:00:00

  • A case-control study of dietary salt intake in pediatric-onset multiple sclerosis.

    abstract:BACKGROUND:High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. OBJECTIVE:We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-co...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.msard.2016.02.011

    authors: McDonald J,Graves J,Waldman A,Lotze T,Schreiner T,Belman A,Greenberg B,Weinstock-Guttman B,Aaen G,Tillema JM,Hart J,Lulu S,Ness J,Harris Y,Rubin J,Candee M,Krupp LB,Gorman M,Benson L,Rodriguez M,Chitnis T,Mar S

    更新日期:2016-03-01 00:00:00

  • Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.

    abstract::Fibrinogen is a protein that plays a key role in blood coagulation and thrombosis and it is involved in several inflammatory processes; in multiple sclerosis (MS) may be related with blood-brain barrier (BBB) disruption. We analysed the relationship between plasma fibrinogen levels and the presence of active lesions o...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.09.033

    authors: Miranda Acuña J,Hidalgo de la Cruz M,Ros AL,Tapia SP,Martínez Ginés ML,de Andrés Frutos CD

    更新日期:2017-11-01 00:00:00

  • Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.

    abstract:BACKGROUND:Underestimation of relapse in multiple sclerosis (MS) is detrimental to the patient as well as to their relationship with their MS healthcare professional (HCP). OBJECTIVE:To obtain direct insight into relapse prevalence, symptoms, and HCP engagement from patients with MS who responded to the Multiple Scler...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.09.002

    authors: Nazareth TA,Rava AR,Polyakov JL,Banfe EN,Waltrip Ii RW,Zerkowski KB,Herbert LB

    更新日期:2018-11-01 00:00:00

  • Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.

    abstract:BACKGROUND:Little is known about the factors associated with the selection of Disease Modifying Agents (DMA) for the management of Multiple Sclerosis (MS) since the introduction of oral DMAs in 2010. OBJECTIVES:To examine the factors associated with initiation of oral DMAs in patients with MS using data from electroni...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102334

    authors: Earla JR,Hutton GJ,Thornton JD,Aparasu RR

    更新日期:2020-10-01 00:00:00

  • Mesenchymal stem cells in experimental autoimmune encephalomyelitis model of multiple sclerosis: A systematic review and meta-analysis.

    abstract:BACKGROUND/AIMS:Mesenchymal stem cells (MSCs) transplantation has been considered a possible therapeutic method for Multiple Sclerosis (MS). However, no quantitative data synthesis of MSCs therapy for MS exists. We conducted a systematic review and meta-analysis to evaluate the effects of MSCs in experimental autoimmun...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102200

    authors: Yanwu Y,Meiling G,Yunxia Z,Qiukui H,Birong D

    更新日期:2020-09-01 00:00:00

  • An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report.

    abstract:BACKGROUND:The acute, fulminant type of Multiple Sclerosis (MS), known as Marburg Disease, has been shown to have poor response to conventional acute treatments typically used for demyelinating diseases. METHODS:We report a 20 y/o postpartum female who was consulted to the Neurology service given findings of subacute ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.03.014

    authors: Avila-Ornelas J,Labat E,Alfonso G,Serrano C,Fiorito F

    更新日期:2019-06-01 00:00:00

  • MSer - A new, neutral descriptor for someone with multiple sclerosis.

    abstract::Lay-members of the public are often involved in grant and ethics review panels. Furthermore grant applications/reports all require some form of lay summary. In response to critical remarks from people with multiple sclerosis (MS) about using the term 'sufferer' as a descriptor, a series of surveys using the internet/s...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2013.06.010

    authors: Baker D,Pepper G,Yauner F,Giovannoni G

    更新日期:2014-01-01 00:00:00

  • Worsening of disability caused by relapses in multiple sclerosis: A different approach.

    abstract:BACKGROUND:In multiple sclerosis (MS) the quantitative role of relapses in Expanded Disability Status Scale (EDSS) worsening beyond the recovery phase is not well known. Most studies have examined the predictive role of early relapses in more distant endpoints. Relapses and worsening may be associated because they coul...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.04.017

    authors: Koch-Henriksen N,Thygesen LC,Sørensen PS,Magyari M

    更新日期:2019-07-01 00:00:00

  • Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries.

    abstract:BACKGROUND:We characterize the variations in availability and affordability of NMO diagnostic testing and treatment by geographic region and country-level income group. METHODS:A structured survey was distributed in English, French, and Spanish in late 2018 to neurologists and other physicians who encounter NMO patien...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.05.013

    authors: Holroyd K,Vogel A,Lynch K,Gazdag B,Voghel M,Alakel N,Patenaude BN,Chiong-Rivero H,Mateen FJ

    更新日期:2019-08-01 00:00:00

  • Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.

    abstract:BACKGROUND:Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102243

    authors: Nali LH,Olival GS,Sousa FTG,de Oliveira ACS,Montenegro H,da Silva IT,Dias-Neto E,Naya H,Spangenberg L,Penalva-de-Oliveira AC,Romano CM

    更新日期:2020-09-01 00:00:00

  • The epidemiology of multiple sclerosis in the Scottish Highlands: Prevalence, incidence and time to confirmed diagnosis and treatment initiation.

    abstract:INTRODUCTION:Although multiple sclerosis (MS) is frequent in the northern hemisphere, there have not been recent epidemiological studies in the Scottish Highlands about MS. OBJECTIVES:To get updated data regarding MS prevalence, incidence and mortality in the Highlands. Time between symptom onset and MS diagnosis was ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102657

    authors: Carod-Artal FJ

    更新日期:2020-11-28 00:00:00

  • CNS demyelination during tofacitinib therapy: First report.

    abstract::Iatrogenic demyelination is a distinct clinical subtype of central nervous system inflammatory disorders. The Janus kinase inhibitor, tofacitinib, is an oral disease-modifying antirheumatic drug that has shown contradictory effects on multiple sclerosis in animal models. In this report, we describe a novel case of rev...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102568

    authors: Massoud F,Ismail II,Al-Hashel JY,Abboud H

    更新日期:2020-11-01 00:00:00

  • Improving MS patients' understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial.

    abstract:BACKGROUND:Multiple Sclerosis (MS) patients find it difficult to understand the complex risk-benefit profiles of disease-modifying drugs. An evidence-based protocol was designed to improve patient's understanding of treatment information: Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS). OBJE...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2021.102737

    authors: Reen GK,Silber E,Langdon DW

    更新日期:2021-01-12 00:00:00